Cargando…

Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date

Huntington disease (HD) is a chronic, genetic, neurodegenerative disease for which there is no cure. The main symptoms of HD are abnormal involuntary movements (chorea and dystonia), impaired voluntary movements (ie, incoordination and gait balance), progressive cognitive decline, and psychiatric di...

Descripción completa

Detalles Bibliográficos
Autores principales:	Squitieri, Ferdinando, de Yebenes, Justo Garcia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4629959/ https://www.ncbi.nlm.nih.gov/pubmed/26604684 http://dx.doi.org/10.2147/DDDT.S65738

Ejemplares similares

Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington’s Disease
por: Waters, Susanna, et al.
Publicado: (2018)

Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model
por: Squitieri, Ferdinando, et al.
Publicado: (2015)

Metoprolol‐pridopidine drug–drug interaction and food effect assessments of pridopidine, a new drug for treatment of Huntington's disease
por: Rabinovich‐Guilatt, Laura, et al.
Publicado: (2017)

Pridopidine activates neuroprotective pathways impaired in Huntington Disease
por: Geva, Michal, et al.
Publicado: (2016)

The effect of mild and moderate renal impairment on the pharmacokinetics of pridopidine, a new drug for Huntington's disease
por: Rabinovich‐Guilatt, L., et al.
Publicado: (2015)

Genetic Counseling in Huntington's Disease: Potential New Challenges on Horizon?
por: Migliore, Simone, et al.
Publicado: (2019)

Pridopidine for the Improvement of Motor Function in Patients With Huntington's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Chen, Shujun, et al.
Publicado: (2021)

Pridopidine Reverses Phencyclidine-Induced Memory Impairment
por: Sahlholm, Kristoffer, et al.
Publicado: (2018)

Aripiprazole in the treatment of Huntington’s disease: a case series
por: Ciammola, Andrea, et al.
Publicado: (2009)

Emotion recognition and inhibitory control in manifest and pre-manifest Huntington's disease: evidence from a new Stroop task
por: Hünefeldt, Thomas, et al.
Publicado: (2020)

Safer Attitude to Risky Decision-Making in Premanifest Huntington’s Disease Subjects
por: D’Aurizio, Giulia, et al.
Publicado: (2019)

Profile of inhaled levodopa and its potential in the treatment of Parkinson’s disease: evidence to date
por: Patel, Ami B, et al.
Publicado: (2018)

Sleep Quality and Related Clinical Manifestations in Huntington Disease
por: Maffi, Sabrina, et al.
Publicado: (2022)

Deep White Matter in Huntington's Disease
por: Phillips, Owen, et al.
Publicado: (2014)

Protection by glia-conditioned medium in a cell model of Huntington disease
por: Ruiz, Carolina, et al.
Publicado: (2012)

DNA instability in replicating Huntington's disease lymphoblasts
por: Cannella, Milena, et al.
Publicado: (2009)

Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to date
por: Pievsky, Daniel, et al.
Publicado: (2016)

Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date
por: Criscitiello, Carmen, et al.
Publicado: (2018)

Current Diagnostic Methods and Non-Coding RNAs as Possible Biomarkers in Huntington’s Disease
por: Pellegrini, Miguel, et al.
Publicado: (2022)

Tractography of the Corpus Callosum in Huntington’s Disease
por: Phillips, Owen, et al.
Publicado: (2013)

Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date [Corrigendum]
Publicado: (2018)

International Guidelines for the Treatment of Huntington's Disease
por: Bachoud-Lévi, Anne-Catherine, et al.
Publicado: (2019)

Current Pharmacological Management in Juvenile Huntington’s Disease
por: Robertson, Lisa, et al.
Publicado: (2012)

Resurrection of sildenafil: potential for Huntington’s Disease, too?
por: Achenbach, Jannis, et al.
Publicado: (2022)

Quantification of the Light Subunit of Neurofilament Protein in Cerebrospinal Fluid of Huntington’s Disease Patients
por: Szejko, Natalia, et al.
Publicado: (2018)

Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date
por: Whitfield, Thomas, et al.
Publicado: (2016)

Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date
por: Facchinetti, Francesco, et al.
Publicado: (2019)

Nitric Oxide Dysregulation in Platelets from Patients with Advanced Huntington Disease
por: Carrizzo, Albino, et al.
Publicado: (2014)

“Spazio Huntington”: Tracing the Early Motor, Cognitive and Behavioral Profiles of Kids with Proven Pediatric Huntington Disease and Expanded Mutations > 80 CAG Repeats
por: Graziola, Federica, et al.
Publicado: (2022)

Rectifying rectifier channels in Huntington disease
por: Proft, Juliane, et al.
Publicado: (2014)

Air pollution and sudden death risk in patients with Parkinson’s disease: Assessing the evidence to date
por: Nejm, Mariana, et al.
Publicado: (2020)

Major Superficial White Matter Abnormalities in Huntington's Disease
por: Phillips, Owen R., et al.
Publicado: (2016)

Pridopidine modifies disease phenotype in a SOD1 mouse model of amyotrophic lateral sclerosis
por: Estévez‐Silva, Héctor M., et al.
Publicado: (2022)

Pridopidine Does Not Significantly Prolong the QTc Interval at the Clinically Relevant Therapeutic Dose
por: Darpo, Borje, et al.
Publicado: (2023)

Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date
por: Dasso, Lily, et al.
Publicado: (2018)

Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date
por: Akamine, Takaki, et al.
Publicado: (2018)

Spotlight on fevipiprant and its potential in the treatment of asthma: evidence to date
por: Kao, Christina C, et al.
Publicado: (2019)

Evidence to date: ranibizumab and its potential in the treatment of retinopathy of prematurity
por: Patel, Samir N, et al.
Publicado: (2019)

NMDA receptor gene variations as modifiers in Huntington disease: a replication study
por: Saft, Carsten, et al.
Publicado: (2011)

Mitochondrial Respiration Changes in R6/2 Huntington’s Disease Model Mice during Aging in a Brain Region Specific Manner
por: Burtscher, Johannes, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jlio5ksa401lf8rq3qrhqb8sqs